Skip to main content

Clinical Trials Using Carboplatin

Review the clinical trials studying carboplatin on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 226-250 of 267

RAPA-201 Therapy of Solid Tumors
Status: Active
Location: Hackensack University Medical Center, Hackensack, New Jersey
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Status: Active
Location: University of Kentucky/Markey Cancer Center, Lexington, Kentucky
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Status: Active
Location: Hackensack University Medical Center, Hackensack, New Jersey
Pegargiminase (ADI-PEG 20), Carboplatin, and Cabazitaxel for the Treatment of Aggressive Variant Metastatic Prostate Cancer
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Status: Active
Location: UCHealth University of Colorado Hospital, Aurora, Colorado
Total Body Irradiation and Hypofractionated Radiation Therapy with Atezolizumab and Chemotherapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, TESSERACT Trial
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Durvalumab and Tremelimumab with or without Chemotherapy for the Treatment of Potentially Resectable Pleural Mesothelioma
Status: Active
Location: Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Status: Active
Location: 5 locations
Split Course Adaptive Radiation Therapy and Immunotherapy with or without Chemotherapy for the Treatment of Stage IV or Locally Advanced Lung Cancer, SiCARIO Study
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
CPI-0209 in Combination with Carboplatin for the Treatment of Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Active
Location: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Pembrolizumab in Combination with Chemotherapy and Image-Guided Surgery for the Treatment of Resectable Pleural Malignant Mesothelioma (MPM)
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Chemoradiotherapy followed by Chemotherapy and Dostarlimab for the Treatment of Stage IIIC Endometrial Cancer
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
A Response-Guided Neoadjuvant Treatment Approach for Treating Stage Ib-III Stomach or Gastroesophageal Junction Cancer, RANT-GC Trial
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Duffy Null-Specific Dose Modifications for the Treatment of Duffy Null Phenotype Multiple Myeloma and Stage II and III Triple Negative Breast Cancer
Status: Active
Location: Dana-Farber Cancer Institute, Boston, Massachusetts
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
Status: Active
Location: See ClinicalTrials.gov
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
Status: Active
Location: See ClinicalTrials.gov
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
Status: Active
Location: See ClinicalTrials.gov
Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)
Status: Active
Location: See ClinicalTrials.gov
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Status: Active
Location: See ClinicalTrials.gov
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Status: Active
Location: See ClinicalTrials.gov
Volrustomig Priming Regimens Exploratory Phase II Platform Study
Status: Active
Location: See ClinicalTrials.gov
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Status: Active
Location: See ClinicalTrials.gov